Article
Virology
Elias Tjarnhage, Diamond Brown, Bjarne Bogen, Tor Kristian Andersen, Gunnveig Grodeland
Summary: This article introduces a viral subunit vaccine that maintains the trimeric form and targets antigen-presenting cells for increased immunogenicity. The vaccine induces strong immune responses and protects mice from lethal challenges with influenza viruses.
JOURNAL OF VIROLOGY
(2023)
Article
Immunology
Erin Sparrow, James G. Wood, Christopher Chadwick, Anthony T. Newall, Siranda Torvaldsen, Ann Moen, Guido Torelli
Summary: The study compares global capacity for production of influenza vaccines in 2019, showing a slight increase in annual seasonal influenza vaccine production capacity and a rising trend in potential annual influenza pandemic vaccine production capacity. However, these estimates should be interpreted cautiously as they are based on assumptions that may impact supply. Pandemic vaccines would not be immediately available, taking four to six months for initial supplies with further time needed to reach maximum capacity.
Article
Immunology
Robert L. Atmar, David I. Bernstein, Patricia Winokur, Sharon E. Frey, Laura S. Angelo, Christopher Bryant, Tammy Ben-Yedidia, Paul C. Roberts, Hana M. El Sahly, Wendy A. Keitel
Summary: This study evaluated the safety and immunogenicity of a candidate vaccine called M-001 as a priming vaccine prior to receiving quadrivalent inactivated influenza vaccine (IIV4). The results showed that M-001 vaccine was safe and induced a subset of persistent polyfunctional CD4+ T cell responses, but it did not improve antibody responses to IIV4.
Article
Multidisciplinary Sciences
Hyesun Jang, Ted M. Ross
Summary: The study found that the humoral response to trivalent seasonal influenza virus vaccines was influenced by rapid antigenic switching of H1 HA. While successful induction of antibodies against H1N1 and H3N2 vaccine components was observed, a strong immune response against CA/09 H1N1 influenza virus negatively influenced the induction of novel humoral responses to other vaccine strains.
Article
Chemistry, Multidisciplinary
Dajeong Kim, Sangwoo Han, Yoonbin Ji, Sunghyun Moon, Hyangsu Nam, Jong Bum Lee
Summary: There is a growing interest in RNA therapeutics globally, and the clinical applications of RNA-based vaccines have further accelerated progress in this field. Multimerization of RNA therapeutics is an attractive approach to improve efficacy, and this review provides an overview of different methods for generating repetitive functional RNAs. The therapeutic and vaccine applications of engineered multimeric RNAs in various diseases are also summarized, highlighting the potential of multimeric RNA as a promising treatment strategy.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Multidisciplinary Sciences
Zubair Akhtar, Fahmida Chowdhury, Mahmudur Rahman, Probir Kumar Ghosh, Md. Kaousar Ahmmed, Md Ariful Islam, Joshua A. Mott, William Davis
Summary: Limited data from several countries indicated reduced seasonal influenza circulation during the COVID-19 pandemic in 2020. A study in Bangladesh found that the 2020 influenza season started later, was shorter, and less intense than previous seasons, likely due to community mitigation measures implemented to control the pandemic. These findings contribute to the growing evidence that influenza seasons were altered globally in 2020.
Article
Multidisciplinary Sciences
David F. Zeigler, Emily Gage, Christopher H. Clegg
Summary: The study introduced a nanoparticle-based vaccine platform for building broadly protective influenza vaccines targeting conserved epitopes, providing long-lasting immunity. Novel epitopes with higher protective potential were identified using protein sequence and structural information in combination, leading to improved antibody responses.
Article
Public, Environmental & Occupational Health
Rui Li, Qian Li, Yiming Liu, Mingwang Shen, Lei Zhang, Guihua Zhuang
Summary: Several candidates of universal influenza vaccine (UIV) have entered phase III clinical trials, which are expected to significantly improve population willingness and coverage. Research shows that UIV can greatly reduce influenza infections, even with low UIV effectiveness and coverage. The 2-month vaccination pattern is more effective in averting influenza infections compared to the 6-month pattern.
EPIDEMIOLOGY AND INFECTION
(2021)
Article
Immunology
Mariia V. Sergeeva, Ekaterina A. Romanovskaya-Romanko, Vera Z. Krivitskaya, Polina A. Kudar, Nadezhda N. Petkova, Kira S. Kudria, Dmitry A. Lioznov, Marina A. Stukova, Yulia A. Desheva
Summary: Neuraminidase-based immunity has the potential to mitigate the impact of novel antigenic variants of influenza viruses. The dynamics of anti-NA antibody response varies depending on the virus subtype, and the persistence of antibodies is different from that of anti-HA antibodies. The level of NA antibodies after vaccination correlates directly with the preexisting titers.
Article
Gerontology
Judy Yuen-man Siu
Summary: The study revealed that participants' negative beliefs about vaccines, low perceived risk of contracting diseases, negative rumors about vaccines, lack of promotion by healthcare providers, perceived risk posed by vaccinating locations, and preference for traditional Chinese medicine were key barriers to receiving seasonal influenza and pneumococcal vaccinations among older adults in Hong Kong.
Review
Virology
Hai Xu, Shanyuan Zhu, Roshini Govinden, Hafizah Y. Chenia
Summary: "Progress in research on avian influenza vaccines" reviews the recent progress and delivery systems of avian influenza vaccines. It provides ideas for the design and development of new vaccines in the avian influenza research community.
Article
Immunology
Hiroaki Kato, Takao Hozawa, Wakaba Fukushima, Eri Nobusawa, Yoshio Hirota
Summary: The Ministry of Health, Labour and Welfare in Japan designates specific virus strains for the seasonal influenza vaccine and domestic manufacturers produce vaccines with the same formulation. The focus has been on the antigenic match between the vaccine strains and epidemic viruses. However, in 2017, the selection system had issues with vaccine productivity, leading to reforms in 2018. A symposium was held to discuss vaccine virus selection, evaluation, and new formulation efforts in Japan.
Article
Immunology
Matthew Newland, David Durham, Jason Asher, John J. Treanor, Jonathan Seals, Ruben O. Donis, Robert A. Johnson
Summary: BARDA addresses challenges in pandemic influenza response by implementing a strategy focused on accelerating vaccine development and production, as well as improving vaccine performance. This strategy involves increasing manufacturing and fill-finish capacity, improving release testing speed, and funding clinical trials to enhance current vaccine utilization. Continued investments in this strategy will further enhance the ability to respond to future emerging pandemic pathogens, as demonstrated by the response to the COVID-19 pandemic.
EXPERT REVIEW OF VACCINES
(2021)
Article
Immunology
Sudha Chivukula, Timothy Plitnik, Timothy Tibbitts, Shrirang Karve, Anusha Dias, Donghui Zhang, Rebecca Goldman, Hardip Gopani, Asad Khanmohammed, Ashish Sarode, Dustin Cooper, Heesik Yoon, Younghoon Kim, Yanhua Yan, Sophia T. Mundle, Rachel Groppo, Adrien Beauvais, Jinrong Zhang, Natalie G. Anosova, Charles Lai, Lu Li, Gregory Ulinski, Peter Piepenhagen, Joshua DiNapoli, Kirill Kalnin, Victoria Landolfi, Ron Swearingen, Tong-Ming Fu, Frank DeRosa, Danilo Casimiro
Summary: The recent approval of mRNA vaccines for emergency use against COVID-19 is likely to accelerate the development of mRNA-based vaccines targeting a wide range of infectious diseases. This vaccine modality promises comparable potency while accelerating the development and deployment of vaccine doses. Demonstrated successfully for single antigen vaccines, the technology could be optimized for complex multi-antigen vaccines.
Review
Economics
Desmond Loong, Ba' Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Mueller, Sharon E. Straus, Andrea C. Tricco, Wanrudee Isaranuwatchai
Summary: Older adults are at high risk of influenza-related complications or hospitalization. This systematic review evaluates the cost-effectiveness of different influenza vaccine options for older adults. The findings suggest that quadrivalent inactivated vaccine (QIV), high-dose trivalent inactivated vaccine (TIV-HD), and adjuvanted trivalent inactivated vaccine (TIV-ADJ) are cost-effective compared to trivalent inactivated vaccine (TIV), with a willingness to pay threshold of $50,000 per quality-adjusted life-year. Future studies should employ robust methodologies, such as real-world evaluations or modeling studies, to account for methodological, structural, and parameter uncertainty.
Article
Immunology
Shane Kelly, Katherine J. L. Jackson, Timothy J. Peters, Dan Suan, Christopher C. Goodnow
Summary: This study successfully identified and characterized PR3-specific B cells from the peripheral blood of patients with PR3 autoantibodies. These cells exhibited specific immunological features, suggesting that PR3 self-reactivity may occur early in B-cell development.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Ana Merino-Vico, Jan Piet van Hamburg, Paul Tuijnenburg, Giulia Frazzei, Aram Al-Soudi, Carlo G. Bonasia, Boy Helder, Abraham Rutgers, Wayel H. Abdulahad, Coen A. Stegeman, Jan-Stephan Sanders, Laura Bergamaschi, Paul A. Lyons, Theo Bijma, Laura van Keep, Kirsten Wesenhagen, Aldo Jongejan, Henric Olsson, Niek de Vries, Taco W. Kuijpers, Peter Heeringa, Sander W. Tas
Summary: B lineage cells play a critical role in ANCA-associated vasculitis (AAV), and the transcription factor NF-kappa B may be a potential therapeutic target for AAV and other autoimmune diseases with prominent B cell involvement.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Christopher Nelke, Thomas Muentefering, Derya Cengiz, Lukas Theissen, Vera Dobelmann, Christina B. Schroeter, Helena Block, Corinna Preu, Alexander P. E. Michels, Stefanie Lichtenberg, Marc Pawlitzki, Steffen Pfeuffer, Niklas Huntemann, Alexander Zarbock, Thorben Briese, Christoph Kittl, Carsten Dittmayer, Thomas Budde, Ingrid E. Lundberg, Werner Stenzel, Sven G. Meuth, Tobias Ruck
Summary: K2P2.1 plays a regulatory role in the autoimmune response of idiopathic inflammatory myopathies (IIMs), by regulating inflammatory cell response, adhesion, and transmigration in both endothelial and skeletal muscle cells. Inhibiting K2P2.1 enhances the inflammatory response, while activating K2P2.1 improves the disease course.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Xuan Zhang, Jun Xia, Ying Jiang, David S. Pisetsky, Josef S. Smolen, Rong Mu, Shengming Dai, Michael E. Weinblatt, Tore K. Kvien, Juan Li, Thomas Doerner, Yu Zhang, Liwei Lu, Chengde Yang, Pingting Yang, Yuan Zhang, Chenchen Xu, Zhan Zhao, Peter E. Lipsky
Summary: The study suggests that TwHF may be as effective as MTX in treating active RA, and combination therapy may be more effective than monotherapy.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, Zihao Zheng, Alex M. Robbins, S. Janna Bashar, Michael F. Denny, Sara S. Mccoy, Irene M. Ong, Miriam A. Shelef
Summary: Rheumatoid factors (RFs) are polyreactive antibodies that can bind disease-specific epitopes. Recent studies have found that RFs in COVID-19 can bind novel IgG epitopes, which provides new insights into the mechanism of RFs.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Johanne Liberatore, Yann Nguyen, Jerome Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puechal, Loic Guillevin, Benjamin Terrier
Summary: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) can lead to decreased gammaglobulin levels, which is associated with an increased risk of relapse and severe infections. Older age, low gammaglobulin levels, and receiving pulses of methylprednisolone at induction therapy are risk factors for gammaglobulin decline.
JOURNAL OF AUTOIMMUNITY
(2024)